[
    [
        {
            "time": "2018-01-03",
            "original_text": "Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Intel",
                    "Procter & Gamble",
                    "Research Reports"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "technology",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "How Did Novartis Perform in 4Q17 and Full-Year 2017?",
            "features": {
                "keywords": [
                    "Novartis",
                    "4Q17",
                    "Full-Year 2017"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "3 Dow Stocks to Buy Amid Tech Selloff",
            "features": {
                "keywords": [
                    "Dow Stocks",
                    "Tech Selloff"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "FDA working on a \"dozen\" policies to boost copycat biotech drugs",
            "features": {
                "keywords": [
                    "FDA",
                    "policies",
                    "biotech drugs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV)",
            "features": {
                "keywords": [
                    "AbbVie",
                    "SAFE Dividend",
                    "Yield"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma",
            "features": {
                "keywords": [
                    "Drug Prices",
                    "Outcome-Based Pricing",
                    "Biopharma"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "start-ups",
                    "innovation"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]